VX-264 – Talk Bio

Actionable Insights Powered by AI

Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme

3 weeks ago talkbio0Tagged Cell Therapy, Clinical Trials, Failure (biologic function), implantable device, Insulin, production, VX-264, zimislecel

Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production

Vertexs second-generation diabetes cell therapy fails early-stage study

3 weeks ago talkbio0Tagged Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880, Failed, VX-264

Failed, VX-264, Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880